The 50% target was negotiated, not predicted — and India’s plan is real but unproven in execution.

Snakebite’s return to the global agenda traces to a single event: in 2015 a manufacturer stopped producing a widely used African antivenom, threatening a treatment vacuum. The resulting advocacy push got WHO to name snakebite a priority disease in 2017, followed by a formal World Health Assembly resolution in 2018.

The 2030 target — halving deaths and disability — came from a WHO expert working group, which judged it achievable based on places where fast, effective treatment had already cut mortality by 85–88%.

• India launched a National Action Plan in March 2024: health-worker training, better ambulance and district-hospital care, regional venom research centres, and public stock-mapping. Execution — costed state plans, published indicators — is the open question.
• Bangladesh has a costed 2023–2028 strategy with 27 specific actions across prevention, first aid, transport and antivenom supply — further along on paper than commonly assumed, though implementation data is still thin.

Available doesn’t mean well-tested — and coverage gaps are real.

Antivenom is still the only proven treatment for a venomous bite, but many South Asian products reached market without modern clinical trials or transparent quality monitoring.

• Standard Indian antivenom targets only the “Big Four” — cobra, krait, Russell’s viper, saw-scaled viper. Regionally important snakes (monocled cobra, banded krait, hump-nosed pit vipers, several north-eastern species) are poorly covered or not covered at all. A 2019 study found weak protection against several of these, including one product that failed against a north Indian krait population.
• WHO has defined target profiles for a well-designed South Asian antivenom and is formally assessing products against that standard — but as of the 2025 report, all eight applications under review were still pending. None can yet be called WHO-approved.
• A 2025 investigation (Bureau of Investigative Journalism / The Guardian) found antivenoms sold into regions where they weren’t matched to local snake species, alongside weak or contested efficacy evidence.

Usually not — and that’s the clearest open gap in the field.

Doctors mostly diagnose envenoming from symptoms — swelling, bleeding, paralysis — since the snake is rarely seen or correctly identified.

• The 20-minute whole blood clotting test — a simple bedside check — performs reasonably well (roughly 72–84% sensitivity, depending on what it’s measured against) but is easy to get wrong with dirty glassware or inconsistent technique.
• A South Indian trial of smartphone thermal imaging found a promising heat signal near bite sites in envenomed patients (94% sensitivity in that study) — but it’s only been tested in one small setting, and it misses bites without local swelling, like some krait bites.

No routinely used test in South Asia can currently identify the biting species. Closing that gap is one of the field’s clearest priorities.

Genuinely promising — and genuinely early. Nothing here is ready to replace antivenom yet.

• Nanobodies — small, lab-made antibody fragments: an 8-part cocktail protected mice against 17 African snake venoms in 2025, proving a fully synthetic antivenom is possible. Not yet built or tested for South Asian snakes.
• Enzyme-blocking drug combinations (marimastat + varespladib): effective in mice, including against Russell’s viper venom. No human trial results yet.
• Human antibodies targeting cobra- and krait-type nerve toxins have protected mice — promising, but partial: they don’t yet cover viper venoms.
• New discovery tools — a decoded cobra genome, lab-grown venom-gland tissue, AI-designed proteins — are speeding up research, but none is an approved treatment.

Community networks and fast transport, not lab breakthroughs, are where the biggest near-term gains sit.

• Programs like Tamil Nadu’s rescue networks, Kerala’s SARPA snake-rescue and alert system, and India’s National Snakebite Project show that local training, mapped responders, and fast transport save lives — often more than high-tech solutions alone.
• Misinformation is a genuine hazard: 2024 reporting on panic in Bangladesh over Russell’s vipers — including false claims that they “chase” people — led to indiscriminate killing of harmless snakes and backlash against rescuers.